Dr Greg Collier discusses Invion’s lupus trial update with BRR Media

MD & CEO, DR GREG COLLIER, DISCUSSES WITH BRR MEDIA THE UPDATE ON INVION’s PHASE II STUDY OF INV103 (ala-Cpn10) IN LUPUS PATIENTS

Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Managing Director and CEO, Dr Greg Collier, as he provides further background to today’s announcement regarding interim data and progress of Invion’s phase II clinical trial in patients with Systemic Lupus Erythematous (SLE or lupus). In this audiocast, Dr Collier discusses:

  • Interim data from the first two cohorts of the phase II clinical trial in lupus patients
  • Next steps for this clinical trial and program
  • INV103 (ala-Cpn10) and Invion’s three drug asset pipeline

To access the audiocast, please visit this link: www.brrmedia.com/event/126913

 

Posted in ASX Releases